000151460 001__ 151460 000151460 005__ 20250310131043.0 000151460 0247_ $$2doi$$a10.2340/00015555-3905 000151460 0248_ $$2sideral$$a126179 000151460 037__ $$aART-2021-126179 000151460 041__ $$aeng 000151460 100__ $$0(orcid)0000-0001-5632-0351$$aMarron S.E.$$uUniversidad de Zaragoza 000151460 245__ $$aQuality of life in hidradenitis suppurativa: Validation of the hsqol-24 000151460 260__ $$c2021 000151460 5060_ $$aAccess copy available to the general public$$fUnrestricted 000151460 5203_ $$aTo date, there are no disease-specific instruments in Spanish to assess quality of life of patients with hidra-denitis suppurativa. A multicentre study was pre-viously carried out in Spain between 2016 and 2017 to develop the Hidradenitis Suppurativa Quality of Life-24 (HSQoL-24), a disease-specific questionnaire to assess quality of life in patients with hidradenitis suppurativa. The objectives of this study are to revali-date the HSQoL-24 in Spanish with a larger sample of patients, and to present the English version. In this multi centre study in Spain, patients with hidradenitis suppurativa completed the HSQoL-24, the Dermatology Life Quality Index and the Skindex-29. The Hurley staging system was used to assess the severity of the disease. Validation of the questionnaire was carried out in 130 patients, of whom 75 (57.7%) were women. This study demonstrates adequate values of reliability and validity of the HSQoL-24, confirming the previous test re-test validation and making this questionnaire one of wide clinical validity in terms of results perceiv-ed by patients. 000151460 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000151460 590__ $$a3.875$$b2021 000151460 591__ $$aDERMATOLOGY$$b18 / 69 = 0.261$$c2021$$dQ2$$eT1 000151460 592__ $$a0.851$$b2021 000151460 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1 000151460 593__ $$aDermatology$$c2021$$dQ1 000151460 594__ $$a4.1$$b2021 000151460 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000151460 700__ $$aGomez-Barrera M. 000151460 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones L.$$uUniversidad de Zaragoza 000151460 700__ $$aGoni-Navarro A. 000151460 700__ $$aVilarrasa-Rull E. 000151460 700__ $$aDiaz-Diaz R.M. 000151460 700__ $$aGarcia-Latasa De Aranibar F.J. 000151460 700__ $$0(orcid)0000-0002-7197-0907$$aCampos-Rodenas R.$$uUniversidad de Zaragoza 000151460 700__ $$aFuentelsaz-Del-barrio V. 000151460 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte-Calzada Y.$$uUniversidad de Zaragoza 000151460 700__ $$aGracia-Cazaña T. 000151460 700__ $$aMorales-Callaghan A.M.$$uUniversidad de Zaragoza 000151460 700__ $$aRos-Abarca S. 000151460 700__ $$aMadrid-Alvarez M.B. 000151460 700__ $$aPuig L. 000151460 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría 000151460 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac 000151460 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000151460 773__ $$g101, 8 (2021), [5 pp.]$$pActa derm.-venereol.$$tActa Dermato-Venereologica$$x0001-5555 000151460 8564_ $$s536867$$uhttps://zaguan.unizar.es/record/151460/files/texto_completo.pdf$$yVersión publicada 000151460 8564_ $$s3585652$$uhttps://zaguan.unizar.es/record/151460/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000151460 909CO $$ooai:zaguan.unizar.es:151460$$particulos$$pdriver 000151460 951__ $$a2025-03-10-12:56:04 000151460 980__ $$aARTICLE